MRNA Oct 2024 55.000 put
| Previous close | 0.5700 |
| Open | 0.5900 |
| Bid | 0.8500 |
| Ask | 1.0900 |
| Strike | 55.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.5900 - 1.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.52k |
Investor's Business DailyIs Moderna Stock A Sell After The Company Slashed Its R&D Budget?
Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?
BloombergCovid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna
(Bloomberg) -- Gritstone Bio Inc., a vaccine developer that once touted its ability to make a next-generation Covid-19 shot, filed for Chapter 11 bankruptcy in Delaware Thursday. Most Read from BloombergSan Francisco to Shut 9% of Public Schools Amid Budget WoesThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsChicago’s $1 Billion Budget Hole Exacerbated by School TurmoilUrban Heat Stress Is Another Disparity in the World’s Most Unequal NationShould Evictions Be Banned After H
ZacksGSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
